PL243119B1 - Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych - Google Patents
Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych Download PDFInfo
- Publication number
- PL243119B1 PL243119B1 PL433567A PL43356720A PL243119B1 PL 243119 B1 PL243119 B1 PL 243119B1 PL 433567 A PL433567 A PL 433567A PL 43356720 A PL43356720 A PL 43356720A PL 243119 B1 PL243119 B1 PL 243119B1
- Authority
- PL
- Poland
- Prior art keywords
- propanamide
- compound
- dcm
- mmol
- meoh
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL433567A PL243119B1 (pl) | 2020-04-16 | 2020-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
| ES21732998T ES3020435T3 (en) | 2020-04-16 | 2021-04-16 | Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders |
| CN202180038326.1A CN115715219B (zh) | 2020-04-16 | 2021-04-16 | 用于治疗神经系统疾病和选择的精神疾患的水溶性、修饰的氨基酸衍生物 |
| PL21732998.6T PL4135840T3 (pl) | 2020-04-16 | 2021-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
| EP24215754.3A EP4527384A3 (en) | 2020-04-16 | 2021-04-16 | Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders |
| US17/996,235 US20230192608A1 (en) | 2020-04-16 | 2021-04-16 | Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders |
| CA3175613A CA3175613A1 (en) | 2020-04-16 | 2021-04-16 | Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders |
| EP21732998.6A EP4135840B1 (en) | 2020-04-16 | 2021-04-16 | Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders |
| PCT/PL2021/050026 WO2021210997A1 (en) | 2020-04-16 | 2021-04-16 | Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL433567A PL243119B1 (pl) | 2020-04-16 | 2020-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL433567A1 PL433567A1 (pl) | 2021-10-18 |
| PL243119B1 true PL243119B1 (pl) | 2023-06-26 |
Family
ID=76483335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL433567A PL243119B1 (pl) | 2020-04-16 | 2020-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych |
| PL21732998.6T PL4135840T3 (pl) | 2020-04-16 | 2021-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21732998.6T PL4135840T3 (pl) | 2020-04-16 | 2021-04-16 | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230192608A1 (es) |
| EP (2) | EP4527384A3 (es) |
| CN (1) | CN115715219B (es) |
| CA (1) | CA3175613A1 (es) |
| ES (1) | ES3020435T3 (es) |
| PL (2) | PL243119B1 (es) |
| WO (1) | WO2021210997A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL240297B1 (pl) | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW288010B (es) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| PL240297B1 (pl) * | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
-
2020
- 2020-04-16 PL PL433567A patent/PL243119B1/pl unknown
-
2021
- 2021-04-16 CA CA3175613A patent/CA3175613A1/en active Pending
- 2021-04-16 EP EP24215754.3A patent/EP4527384A3/en active Pending
- 2021-04-16 CN CN202180038326.1A patent/CN115715219B/zh active Active
- 2021-04-16 EP EP21732998.6A patent/EP4135840B1/en active Active
- 2021-04-16 PL PL21732998.6T patent/PL4135840T3/pl unknown
- 2021-04-16 US US17/996,235 patent/US20230192608A1/en active Pending
- 2021-04-16 ES ES21732998T patent/ES3020435T3/es active Active
- 2021-04-16 WO PCT/PL2021/050026 patent/WO2021210997A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4135840A1 (en) | 2023-02-22 |
| CN115715219A (zh) | 2023-02-24 |
| PL4135840T3 (pl) | 2025-05-12 |
| EP4135840B1 (en) | 2025-01-08 |
| EP4527384A3 (en) | 2025-07-02 |
| CN115715219B (zh) | 2026-01-06 |
| CA3175613A1 (en) | 2021-10-21 |
| EP4527384A2 (en) | 2025-03-26 |
| PL433567A1 (pl) | 2021-10-18 |
| US20230192608A1 (en) | 2023-06-22 |
| WO2021210997A1 (en) | 2021-10-21 |
| ES3020435T3 (en) | 2025-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0179661B1 (ko) | N-페닐알킬 치환된 알파-아미노 카복스아미드 유도체 및 이를 포함하는 약제학적 조성물 및 이의 제조방법 | |
| US12331019B2 (en) | Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | |
| US5731348A (en) | Alkylcarboxy amino acids-modulators of the kainate receptor | |
| EP0731085A1 (en) | Stilbene derivatives and pharmaceutical compositions containing them | |
| KR20010108032A (ko) | 갑상선 수용체 리간드 | |
| FI94955C (fi) | Menetelmä uusien terapeuttisesti aktiivisten substituoitujen 7-hydroksi-2,3,4,5-tetrahydro-1H-3-bentsatsepiinien karbamiinihappoestereiden valmistamiseksi | |
| PL243119B1 (pl) | Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych | |
| JP2022522949A (ja) | (2,5-ジオキソピロリジン-1-イル)(フェニル)-アセトアミド誘導体、および神経疾患の処置におけるその使用 | |
| LT3960B (en) | Process for preparing hypoglycemic compounds | |
| Weigl et al. | Synthesis of chiral non-racemic 3-(dioxopiperazin-2-yl) propionic acid derivatives | |
| US20060135785A1 (en) | Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof | |
| PL175707B1 (pl) | Nowe estry 1-aryloksy-3-alkiloamino-2-propanolu | |
| US20250042848A1 (en) | DEUTERATED FUNCTIONALIZED DERIVATIVES OF alpha-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| HK40082537A (en) | Water-soluble, modified amino acid derivatives for treatment of neurological diseases and selected psychiatric disorders | |
| HK40064412A (en) | Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | |
| CN119661447A (zh) | 一种(3r,6r)-1-十二烷基-3,6-二异丁基哌嗪-2,5-二酮的制备方法 |